Literature DB >> 9008290

Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation.

H Kook1, F Goldman, R Giller, N Goeken, C Peters, M Comito, S Rumelhart, M Holida, N Lee, M Trigg.   

Abstract

Reconstitution of the immune system following T-cell-depleted bone marrow transplantation (BMT) in children has yet to be fully elucidated. Thus, we prospectively studied the recovery of immune function in 64 children who underwent T-lymphocyte-depleted marrow transplants using either matched family member donors or matched unrelated donors. We measured in vitro posttransplantation proliferative responses to phytohemagglutinin (PHA), concanavalin A, pokeweed mitogen, and Candida albicans antigen and assessed unidirectional allogeneic mixed-lymphocyte culture (MLC) responses at various times. A total of 129 healthy individuals served as normal controls for these assays. Responses to T-cell mitogens normalized within 12 months posttransplantation, while MLC responses normalized by 9 months. The presence of graft-versus-host disease (grade II or greater) and cytomegalovirus infection was associated with delays in immune function recovery. Importantly, immune function recovery correlated temporally with a rise in peripheral lymphocyte count. In contrast, the CD4/CD8 ratio was not predictive of immune recovery. Knowledge of immune function recovery may guide clinicians in devising strategies to minimize the risk of infection post-BMT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008290      PMCID: PMC170484          DOI: 10.1128/cdli.4.1.96-103.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  36 in total

1.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors.

Authors:  D R Noel; R P Witherspoon; R Storb; K Atkinson; K Doney; E M Mickelson; H D Ochs; R P Warren; P L Weiden; E D Thomas
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

2.  The graft-versus-host reaction and immune function. I. T helper cell immunodeficiency associated with graft-versus-host-induced thymic epithelial cell damage.

Authors:  M Seddik; T A Seemayer; W S Lapp
Journal:  Transplantation       Date:  1984-03       Impact factor: 4.939

3.  Regeneration of T cell subpopulations after bone marrow transplantation: cytomegalovirus infection and lymphoid subset imbalance.

Authors:  R W Schroff; R P Gale; J L Fahey
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

4.  Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery.

Authors:  H Kook; F Goldman; D Padley; R Giller; S Rumelhart; M Holida; N Lee; C Peters; M Comito; D Huling; M Trigg
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

5.  In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non-T lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy.

Authors:  R P Witherspoon; L G Lum; R Storb; E D Thomas
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

6.  Is cytomegalovirus infection a major cause of T cell alterations after (autologous) bone-marrow transplantation?

Authors:  L F Verdonck; G C de Gast
Journal:  Lancet       Date:  1984-04-28       Impact factor: 79.321

7.  Inhibiton of IL 2 production after human allogeneic bone marrow transplantation.

Authors:  O Azogui; E Gluckman; D Fradelizi
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

8.  Human bone marrow allograft recipients: production of, and responsiveness to, interleukin 2.

Authors:  H S Warren; K Atkinson; R G Pembrey; J C Biggs
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

9.  T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets.

Authors:  K Atkinson; J A Hansen; R Storb; S Goehle; G Goldstein; E D Thomas
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

10.  Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2.

Authors:  T Mori; M S Tsoi; S Gillis; E Santos; E D Thomas; R Storb
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

View more
  5 in total

Review 1.  Post-transplant immune recovery and the implication for infection risk.

Authors:  Michael E Trigg
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Stem cell through present and future.

Authors:  Vijay K Sharma; Utpal K Singh; Rajniti Prasad; Sophie Fletcher
Journal:  Indian J Pediatr       Date:  2009-04-18       Impact factor: 1.967

Review 3.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

Review 4.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27

5.  Expansion of multipotent stem cells from the adult human brain.

Authors:  Wayne Murrell; Emily Palmero; John Bianco; Biljana Stangeland; Mrinal Joel; Linda Paulson; Bernd Thiede; Zanina Grieg; Ingunn Ramsnes; Håvard K Skjellegrind; Ståle Nygård; Petter Brandal; Cecilie Sandberg; Einar Vik-Mo; Sheryl Palmero; Iver A Langmoen
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.